# US 2026/0028402 A1 · Anti-cd100 antibody and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0028402 A1
- Document ID: US20260028402A1
- Status: Published application
- Kind: A1
- Application number: 19/134,118
- Filed: 2023-10-31
- Published: 2026-01-29
- Earliest claimed: 2022-11-30
- Assignees: Sanyou Biopharmaceuticals Co., Ltd.
- Applicants: Sanyou Biopharmaceuticals Co., Ltd.
- Inventors: Shuangqi LI; Guojun LANG; Xintian YAN; Yuhao HU; Zhen ZHANG; Liyan WANG; Xiaopeng FANG; Peifang XU; Yangyang HAN; Yuqi REN; Qiangqiang DENG; Xue GAO
- Web page: https://patentgrep.com/patent/US20260028402A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- C07K 14/525: Tumour necrosis factor [TNF]
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C12N 5/00: Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques A01H4/00)
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to the field of biomedicines. Specifically, the present invention relates to an anti-CD100 antibody and a use thereof, and a pharmaceutical composition or pharmaceutical combination containing the antibody and a use thereof. The present invention further provides a nucleic acid molecule and expression vector for encoding the antibody and a method for producing the antibody.

## Claims

### Claim 1

An antibody or an antigen-binding fragment thereof against CD100, comprising an immunoglobulin single variable domain, wherein
the single variable domain comprises three CDR sequences in the amino acid sequence of the single variable domain as set forth in SEQ ID NO: 4 or a variant thereof; or
the single variable domain comprises three CDR sequences in the amino acid sequence of the single variable domain as set forth in SEQ ID NO: 8 or a variant thereof;
wherein the variant differs from the CDR sequence from which it is derived by addition, deletion or substitution of no more than 2 amino acids.

### Claim 2 (depends on 1)

The antibody or antigen-binding fragment thereof according to claim 1, wherein the single variable domain comprises:
(a) a CDR1 sequence as set forth in SEQ ID NO: 1; a CDR2 sequence as set forth in SEQ ID NO: 2; and a CDR3 sequence as set forth in SEQ ID NO: 3; or
(b) a CDR1 sequence as set forth in SEQ ID NO: 5; a CDR2 sequence as set forth in SEQ ID NO: 6; and a CDR3 sequence as set forth in SEQ ID NO: 7.

### Claim 3 (depends on 1)

The antibody or antigen-binding fragment thereof according to claim 1, wherein the immunoglobulin single variable domain is a variable domain of a heavy chain antibody (VHH).

### Claim 4 (depends on 1)

The antibody or antigen-binding fragment thereof according to claim 1, wherein the antibody or antigen-binding fragment thereof comprises an immunoglobulin single variable domain, wherein
the single variable domain comprises an amino acid sequence as set forth in SEQ ID NO: 4 or an amino acid sequence having at least 85%, at least 90%, at least 95% or higher sequence identity to SEQ ID NO: 4; or
the single variable domain comprises an amino acid sequence as set forth in SEQ ID NO: 8 or an amino acid sequence having at least 85%, at least 90%, at least 95% or higher sequence identity to SEQ ID NO: 8.

### Claim 5 (depends on 1)

The antibody or antigen-binding fragment thereof according to claim 1, which is a single domain antibody, a heavy chain antibody, a humanized antibody or a chimeric antibody.

### Claim 6 (depends on 1)

The antibody or antigen-binding fragment thereof according to claim 1, wherein the immunoglobulin single variable domain is capable of being fused to an additional molecule;
preferably, the additional molecule is an Fc domain of an immunoglobulin;
more preferably, the additional molecule is an Fc domain of an immunoglobulin G4 (IgG4SP).

### Claim 7 (depends on 6)

The antibody or antigen-binding fragment thereof according to claim 6, wherein
the antibody or antigen-binding fragment thereof comprises an amino acid sequence as set forth in SEQ ID NO: 9 or an amino acid sequence having at least 85%, at least 90%, at least 95% or higher sequence identity to SEQ ID NO: 9; or
the antibody or antigen-binding fragment thereof comprises an amino acid sequence as set forth in SEQ ID NO: 10 or an amino acid sequence having at least 85%, at least 90%, at least 95% or higher sequence identity to SEQ ID NO: 10.

### Claim 8 (depends on 1)

The antibody or antigen-binding fragment thereof according to claim 1, which is a humanized antibody or an antigen-binding fragment thereof.

### Claim 9 (depends on 8)

The antibody or antigen-binding fragment thereof according to claim 8, wherein the humanized antibody or antigen-binding fragment thereof comprises an immunoglobulin single variable domain, wherein
the single variable domain comprises an amino acid sequence as set forth in SEQ ID NO: 11, 13 or 15 or an amino acid sequence having at least 85%, at least 90%, at least 95% or higher sequence identity to SEQ ID NO: 11, 13 or 15; or
the single variable domain comprises an amino acid sequence as set forth in SEQ ID NO: 17, or an amino acid sequence having at least 85%, at least 90%, at least 95% or higher sequence identity to SEQ ID NO: 17;
or
the humanized antibody or antigen-binding fragment thereof comprises an amino acid sequence as set forth in SEQ ID NO: 12, 14 or 16 or an amino acid sequence having at least 85%, at least 90%, at least 95% or higher sequence identity to SEQ ID NO: 12, 14 or 16; or
the humanized antibody or antigen-binding fragment thereof comprises the amino acid sequence as set forth in SEQ ID NO: 18 or an amino acid sequence having at least 85%, at least 90%, at least 95% or higher sequence identity to SEQ ID NO: 18.

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12 (depends on 1)

A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 13 (depends on 1)

A pharmaceutical combination comprising the antibody or antigen-binding fragment thereof according to claim 1 and an anti-PD-L1 antibody or an antigen-binding fragment thereof.

### Claim 14 (depends on 13)

The pharmaceutical combination according to claim 13, wherein the anti-PD-L1 antibody or antigen-binding fragment thereof specifically recognizes and binds to PD-L1, wherein the anti-PD-L1 antibody or antigen-binding fragment thereof comprises an immunoglobulin single variable domain;
preferably, the immunoglobulin single variable domain comprises:
a CDR1 sequence as set forth in SEQ ID NO: 20,
a CDR2 sequence as set forth in SEQ ID NO: 21, and
a CDR3 sequence as set forth in SEQ ID NO: 22;
more preferably, the immunoglobulin single variable domain comprises: 1) an amino acid sequence as set forth in SEQ ID NO: 23; or 2) an amino acid sequence having at least 85%, at least 90%, at least 95% or higher sequence identity to SEQ ID NO: 23.

### Claim 15 (depends on 14)

The pharmaceutical combination according to claim 14, wherein the anti-PD-L1 antibody or antigen-binding fragment thereof further comprises an Fc fragment of a human IgG1;
preferably, the PD-L1 antibody or antigen-binding fragment thereof comprises an amino acid sequence as set forth in SEQ ID NO: 24 or an amino acid sequence having at least 85%, at least 90%, at least 95% or higher sequence to SEQ ID NO: 24.

### Claim 16 (depends on 13)

The pharmaceutical combination according to claim 13, which is a pharmaceutical composition or a kit.

### Claim 17 (depends on 1)

A method for treating a cancer in a subject comprising administering to the subject a therapeutically effective amount of the antibody or antigen-binding fragment thereof according to claim 1, a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof and a pharmaceutically acceptable carrier, or a pharmaceutical combination comprising the antibody or antigen-binding fragment thereof and an anti-PD-L1 antibody or an antigen-binding fragment thereof;
preferably, the cancer is a hematological tumor or a solid tumor.

### Claim 18 (depends on 17)

The method according to claim 17, wherein
the solid tumor comprises squamous cell carcinoma, adenocarcinoma, basal cell carcinoma, renal cell carcinoma, breast ductal carcinoma, soft tissue sarcoma, osteosarcoma, melanoma, small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, peritoneal cancer, hepatocellular carcinoma, gastrointestinal cancer, gastric cancer, pancreatic cancer, neuroendocrine carcinoma, glioblastoma, cervical cancer, ovarian cancer, bladder cancer, brain cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial cancer or uterine cancer, esophageal cancer, salivary gland cancer, kidney cancer, liver cancer, prostate cancer, vulvar cancer, thyroid cancer or head and neck cancer;
the hematological tumor comprises leukemia, lymphoma, myeloma, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, hairy cell leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, or multiple myeloma.

### Claim 19 (depends on 17)

The method according to claim 17, further comprising administering one or more therapeutic agents selected from the group consisting of a chemotherapeutic agent, a radioisotope, an immune checkpoint inhibitor, and a tumor antigen targeting drug.

### Claim 20 (depends on 1)

An isolated nucleic acid molecule encoding the antibody or antigen-binding fragment thereof according to claim 1.

### Claim 21 (depends on 20)

An expression vector or a host cell comprising the nucleic acid molecule according to claim 20.

### Claim 22

(canceled)

### Claim 23 (depends on 1)

A method for producing the antibody or antigen-binding fragment thereof according to claim 1, comprising:
a) culturing a host cell under suitable conditions to express the antibody or antigen-binding fragment thereof, wherein the host cell comprises an isolated nucleic acid molecule encoding the antibody or antigen-binding fragment thereof; and
b) isolating the antibody or antigen-binding fragment thereof from the host cell or a culture thereof.
